On Jul. 27, 2020, FUJIFILM Diosynth Biotechnologies (FDB) and Texas A&M announced they mass will produce vaccines as part of an agreement between the federal government and the Center for Innovation in Advanced Development and Manufacturing.

FDB was slated to use the reserved capacity at one of the FDB facilities for the COVID-19 vaccine candidate of Novavax, NVX-CoV2373.

Valued at about $265 million, the task order also accelerated a planned expansion at the FDB facility by helping fund new equipment for use in the current pandemic and in future emergencies.